EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo

Vita Golubovskaya, John Sienkiewicz, Jinying Sun, Shiming Zhang iD, Yanwei Huang, Hua Zhou, Hizkia Harto, Shirley Xu, Robert Berahovich, Lijun Wu

International Journal of Molecular Sciences · 29.08.2023 · 24 (17) · 13364

DOI: 10.3390/ijms241713364 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.08.2023. Verfasst von Vita Golubovskaya und 9 weiteren Autor:innen. Beteiligte Einrichtung: Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA 94806, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Multiple Myeloma. Die Arbeit wurde bisher 68-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Promab Biotechnologies.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Natural killer (NK) cells are cytotoxic lymphocytes that are critical for the innate immune system. Engineering NK cells with chimeric antigen receptors (CARs) allows CAR-NK cells to target tumor antigens more effectively. In this report, we present novel CAR mRNA-LNP (lipid nanoparticle) technology to effectively transfect NK cells expanded from primary PBMCs and to generate functional CAR-NK cells. CD19-CAR mRNA and BCMA-CAR mRNA were embedded into LNPs that resulted in 78% and 95% CAR expression in NK cells, respectively. BCMA-CAR-NK cells after transfection with CAR mRNA-LNPs killed multiple myeloma RPMI8226 and MM1S cells and secreted IFN-gamma and Granzyme B in a dose-dependent manner in vitro. In addition, CD19-CAR-NK cells generated with CAR mRNA-LNPs killed Daudi and Nalm-6 cells and secreted IFN-gamma and Granzyme B in a dose-dependent manner. Both BCMA-CAR-NK and CD19-CAR-NK cells showed significantly higher cytotoxicity, IFN-gamma, and Granzyme B secretion compared with normal NK cells. Moreover, CD19-CAR-NK cells significantly blocked Nalm-6 tumor growth in vivo. Thus, non-viral delivery of CAR mRNA-LNPs can be used to generate functional CAR-NK cells with high anti-tumor activity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenMultiple MyelomaHumansGranzymesB-Cell Maturation AntigenKiller Cells, NaturalAdaptor Proteins, Signal TransducingAntigens, CD19

Stichwörter der Autor:innen

chimeric antigen receptorimmunotherapyleukemialipid nanoparticlesmRNAmultiple myelomanatural killer cellstumor

Substanzen

Receptors, Chimeric AntigenGranzymesB-Cell Maturation AntigenAdaptor Proteins, Signal TransducingAntigens, CD19

Autor:innen und Institutionen

  • Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA 94806, USA.
  • Laboratory for Critical Quality Attributes of Cell Therapy Products, Forevertek Biotechnology, Janshan Road, Changsha Hi-Tech Industrial Development Zone, Changsha 410205, China.

ORCID-Profile: Shiming Zhang

Förderung

  • Promab Biotechnologies

Zitieren

APA

Golubovskaya, V., Sienkiewicz, J., Sun, J., Zhang, S., Huang, Y., Zhou, H., Harto, H., Xu, S., Berahovich, R., & Wu, L. (2023). CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo. International Journal of Molecular Sciences, 24(17), 13364. https://doi.org/10.3390/ijms241713364

Vancouver

Golubovskaya V, Sienkiewicz J, Sun J, Zhang S, Huang Y, Zhou H, et al. CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo. International Journal of Molecular Sciences. 2023;24(17):13364. doi:10.3390/ijms241713364

BibTeX
@article{Golubovskaya2023,
  author = {Golubovskaya, Vita and Sienkiewicz, John and Sun, Jinying and Zhang, Shiming and Huang, Yanwei and Zhou, Hua and Harto, Hizkia and Xu, Shirley and Berahovich, Robert and Wu, Lijun},
  title = {CAR-NK Cells Generated with mRNA-LNPs Kill Tumor Target Cells In Vitro and In Vivo},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {17},
  pages = {13364},
  doi = {10.3390/ijms241713364}
}
Kostenlos starten →